You are here

Signet Laboratories Releases DJ-1 Predictive Diagnostic for Parkinson’s Disease

DEDHAM, Mass., July 9 /PRNewswire/ -- In a new contribution to the fight against Parkinson's Disease, Signet Laboratories, Inc., a pioneer in evidence- based medicine (EviMed), today announced the release of its DJ-1 monoclonal antibody, which is a potential diagnostic for predicting the emergence of the disease.

"Parkinson's Disease currently affects over a half-million people in the U.S. alone, with 50,000 new cases diagnosed each year," said Dr. Richard D. Gill, President and CEO of Signet. "Unfortunately, Parkinson's is a very difficult disease to detect, and neurologists must rely on an evaluation of symptoms, followed by administration of anti-Parkinson's drugs to see if the patient responds. This is a long and difficult process, and sometimes leads to incorrect diagnoses that prevent a patient's effective treatment."

The DJ-1 protein has been recently identified as causative of early-onset, autosomal recessive Parkinson's Disease. Signet has developed a monoclonal antibody for detecting DJ-1, to map the protein in regions of the brain associated with the incidence of Parkinson's. DJ-1 could prospectively provide an accurate testing regime for diagnosing the elusive disorder.

About Signet Laboratories, Inc.

Signet Laboratories, Inc. is a pioneering evidence-based medicine (EviMed) company that is committed to developing and commercializing predictive diagnostics and preventive drugs and therapies for critical disease states.

Evidence-based medicine is the treatment of diseases prior to their full manifestation, with the goal of reducing their occurrence and preventing disease progression by early identification of patients with increased risk factors.

Drawing on long experience in developing diagnostic assays and antibodies for disease detection and treatment, Signet's mission is to create novel diagnostics and drugs for patients at risk for cancer, sepsis and renal failure (SARF), neurodegenerative diseases including Alzheimer's, Parkinson's and Huntington's, and prion diseases such as "Mad Cow" and vCJD.

In addition to diagnostics, drugs and therapies, Signet offers a complete product line of over 800 manufactured antibodies, ELISA kits, detection products and accessories in an FDA registered facility. Signet products are available online, at http://www.signetlabs.com/. For more information, contact Terri Daly at (781) 915-1404, or via email: tdaly@signetlabs.com.

Recent Headlines

First Devices Cleared for Diagnostic Testing Via Throat, Rectum Specimens
First New Medication for Seizure Clusters in More Than Two Decades
Novel, Low-cost Device Highly Accurate at Screening Newborn Jaundice
Mode Delivers Antivirals Safely, Cheaply to Remote Regions
Averts Disease Worsening, Reduces Potential for Blindness
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Overeager Use of Recommendations Creates Problems
Artificial Intelligence Enables Platform to Detect Amyloid PET Status